Preferred Label : Pritumumab;
NCIt synonyms : Immunoglobulin G, Anti-(Human Vimentin) (Human Monoclonal CLN G11 Gamma1-chain), Disulfide
With Human Monoclonal CLN G11 Kappa-Chain, Dimer; ACA-11;
NCIt definition : A naturally-produced human immunoglobulin G1 (IgG1) kappa antibody derived from a
tumor-specific B-lymphocyte isolated from the regional draining lymph node of a patient
with cervical carcinoma and targeted against the cell surface expressed vimentin,
ecto-domain vimentin (EDV), with potential immunomodulating and antineoplastic activities.
Upon administration, pritumumab targets and binds to EDV, which is expressed on a
variety of tumor cell types but is not expressed by normal tissues and cells. This
induces tumor cell death by antibody-dependent cell-mediated cytotoxicity (ADCC),
and inhibits growth of EDV-expressing tumor cells. Pritumumab is able to penetrate
the blood-brain barrier (BBB). Vimentin, an intracellular cytoskeletal protein, is
overexpressed during epithelial-to-mesenchymal transition (EMT).;
UNII : Z6Q90D1G53;
CAS number : 499212-74-7;
Molecule name : CLN-IgG; CLNH11;
NCI Metathesaurus CUI : CL1382576;
Origin ID : C170350;
UMLS CUI : C5417802;
Semantic type(s)
- concept_is_in_subset
